Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension
Authors:
- Ben SchwerdtfegerBSBen Schwerdtfeger
- Gunnar KleinGKGunnar Klein
- Tibor KempfTKTibor Kempf
- Arnd SchaeferASArnd Schaefer
- Julia-Marie KnappJKJulia-Marie Knapp
- Michael NiehausMNMichael Niehaus
- Thomas KorteTKThomas Korte
- Marius M. HoeperMHMarius M. Hoeper
- 1 January 2007
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 153 (1) , 127-132
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Pulmonary Arterial HypertensionCirculation, 2004
- Cellular and molecular pathobiology of pulmonary arterial hypertensionJACC, 2004
- Sitaxsentan Therapy for Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Beraprost therapy for pulmonary arterial hypertensionJACC, 2003
- Primary pulmonary hypertensionThe Lancet, 2003
- Clinical Efficacy of Sitaxsentan, an Endothelin-A Receptor Antagonist, in Patients With Pulmonary Arterial HypertensionChest, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Primary Pulmonary HypertensionCirculation, 2000
- Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled TrialAnnals of Internal Medicine, 2000
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996